0000000000345078

AUTHOR

L. Jia

showing 3 related works from this author

Status of the g-2 experiment at BNL

1999

The muon g-2 experiment at Brookhaven has successfully completed two exploratory runs using pion injection and direct muon injection for checkout and initial data taking. The main components of the experiment, which include the pion beam line, the superconducting storage ring and inflector magnets, the muon kicker and the lead-scintillating fiber calorimeters have been satisfactorily commissioned. First results on the anomalous magnetic moment of the positive muon from pion injection are in good agreement with previous experimental results for a(mu+) and a(mu-) from CERN and of comparable accuracy (13 ppm). Analysis of the 1998 muon injection run is in progress and expected to improve the p…

PhysicsNuclear and High Energy PhysicsParticle physicsLarge Hadron ColliderMuonMesonAnomalous magnetic dipole momentPhysics::Instrumentation and DetectorsMUONAtomic and Molecular Physics and OpticsNuclear physicsPionDIPOLE-MOMENTAntimatterPhysics::Accelerator PhysicsHigh Energy Physics::ExperimentANOMALOUS MAGNETIC-MOMENTStorage ringLeptonNuclear physics b-Proceedings supplements
researchProduct

Association Between Tumor Egfr and Kras Mutation Status and Clinical Outcomes in Nsclc Patients Randomized to Sorafenib Plus Best Supportive Care (BS…

2012

ABSTRACT Background Tumor EGFR and KRas mutations are both predictive and prognostic biomarkers in patients with advanced NSCLC. We analyzed the correlation between these biomarkers and treatment outcomes in a phase III trial of 3rd/4th line sorafenib in patients with NSCLC. Methods The global, randomized, placebo-controlled MISSION trial enrolled 703 patients with advanced relapsed/refractory NSCLC of predominantly non-squamous histology. The primary study endpoint was overall survival (OS). EGFR and KRas mutations were analyzed in archival tumor samples and in circulating tumor DNA isolated from plasma. Results Tumor and/or plasma mutation data were available from 347 patients (49%). EGFR…

OncologySorafenibmedicine.medical_specialtyProportional hazards modelbusiness.industryHematologymedicine.disease_causePlacebomedicine.diseaseBreast cancerOncologyEgfr mutationInternal medicineMedicineBiomarker (medicine)KRASStage (cooking)businessmedicine.drugAnnals of Oncology
researchProduct

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.201…

2016

non presente

Molecular Biology; Cell BiologyCell BiologySettore BIO/06 - Anatomia Comparata E CitologiaMolecular Biology
researchProduct